Monographie - Etoposide phosphate - Stabilis 4.0

Zadnji put ažurirano :
19/11/2024

lijek protiv karcinoma

Etoposide phosphate

injekcija

Stabilizacija rješenja

Stabilnost mješavine

Stabilizacijski faktor

Kompatibilnosti

način davanja lijeka

Bibliografija

pdf

Kemijska struktura

Nekomercijalni

Nekomercijalni

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Etopofos	Argentina, Austrija, Danska, Finska, Norveška, Švedska
Etopophos	Belgija, Bugarska, Francuska, Izrael, Južna Afrika, Luksemburg, Nizozemska, Njemačka, novi Zeland, Poljska, S A D, Švicarska, Velika Britanija
Nexvep	Brazil
Toposar	S A D

Bibliografija

injekcija

Bibliografija : Etoposide phosphate

	Vrsta	Publikacija
1410	Časopis	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1411	Časopis	Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc 1999 ; 39: 146-150.
1423	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1606	Časopis	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	Časopis	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Časopis	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Časopis	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Časopis	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Časopis	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3644	Laboratorija	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3655	Laboratorija	Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2016
3838	Laboratorija	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4102	Časopis	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.

Mentions Légales